Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 11, 2026
TickeronGET DAILY SIGNALS
Stryker (SYK) Slides -22% in 30 Days as Supply Concerns Mount

Stryker (SYK) Slides -22% in 30 Days as Supply Concerns Mount

Key Takeaways

  • Stryker (SYK) shares fell about 22% over the last 30 days, sliding from roughly $347 to near $270 and trading at or near 52-week lows.
  • The sell-off accelerated in early September after management warned that manufacturing and supply problems in its peripheral vascular business would persist into the fourth quarter.
  • Softer-than-expected summer seasonality in the joint replacement franchise added to investor concerns about the second-half growth ramp.
  • Several analysts trimmed price targets following the company's Wells Fargo Healthcare Conference commentary, though the consensus rating remains broadly positive.
  • Shares are down roughly 21% year to date and about 28% from their 52-week closing high of $392.76.

Stryker (SYK) Company Overview and Market Position

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company designs, manufactures, and markets a broad portfolio of products across orthopedics, medical and surgical equipment, and neurotechnology. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room and emergency-care equipment, endoscopy and surgical navigation systems, and devices used to treat neurovascular conditions such as stroke.

Stryker is one of the largest players in the medical device industry and is widely followed by investors for its diversified revenue base, its Mako robotic-assisted surgery platform, and a track record of steady organic growth and margin expansion. Its scale across hospital capital equipment and implant consumables gives it meaningful competitive strength, while also exposing results to hospital capital budgets and procedure-volume trends. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stryker (SYK) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, SYK shares declined approximately 22%, falling from a close near $347 in mid-August to about $270 in early September. The decline was not linear; the stock held in the mid-$330s through late August before breaking down sharply, with a single-session drop of more than 8% on September 8 following management's conference commentary. The shares have since continued lower and are trading near their 52-week lows.

The move extends a longer downtrend. For much of the past year, Stryker has trended lower from an all-time closing high of $403.53 reached in July 2025. Over the most recent quarter, the decline has accelerated, with the stock falling from the mid-$340s in early August toward the $270 level. As of early September, the shares were down roughly 21% year to date and about 28% from their 52-week closing high.

What Drove SYK Stock Price in the Last 30 Days

The sharpest leg of the decline followed Stryker's presentation at the Wells Fargo Healthcare Conference in Boston. Chief Financial Officer Preston Wells told investors that a manufacturing issue affecting the peripheral vascular business—originally expected to be resolved in the third quarter—would continue into the fourth quarter. Wells said the supply constraint was preventing the company from reaching full inventory levels at customers and limiting its ability to win new business.

Wells also flagged softer-than-expected trends in the joint replacement business, noting that stronger June results were followed by more typical summer seasonality rather than the acceleration management had anticipated. These comments raised questions about whether the company can achieve its full-year organic growth guidance range of 8.3% to 9.3%.

The cautious tone prompted a wave of analyst revisions. Wells Fargo lowered its price target to $348 from $418, Citigroup trimmed its target to $360 from $399, and BMO Capital reduced its target to $317 from $369. Wolfe Research had already downgraded the stock to a peer-perform rating in mid-August. Insider selling—totaling more than $118 million over a roughly 90-day period—also contributed to the cautious sentiment. From what I see, this combination of factors has clearly weighed on sentiment.

What Drove SYK Stock Performance Over the Last Quarter

The quarterly slide reflects a broader loss of momentum rather than a single event. Stryker entered the period having beaten Wall Street expectations in its second-quarter results, posting adjusted earnings of $3.69 per share and revenue of $6.59 billion. However, investor focus quickly shifted to execution risks in the back half of the year, including supply-chain disruptions, an earlier cyberattack, and softer procedure trends in hips and knees globally.

The medical device sector has faced renewed scrutiny around hospital capital spending and procedure volumes, and Stryker's premium valuation made the stock vulnerable to any growth concerns. As estimates were trimmed and multiple analysts cut targets, the shares gave up their earlier gains and moved decisively lower. The result is a stock now trading near levels last seen in late 2023.

SYK Stock Forecast Drivers: What Investors Should Watch Next

Investors will be watching several factors in the coming months. The most important near-term catalyst is Stryker's third-quarter earnings report, where management is expected to provide a more detailed update on supply recovery in peripheral vascular and on joint replacement demand. September was flagged by management as a key month for judging whether full-year guidance remains achievable.

Additional areas to monitor include progress in resolving manufacturing constraints, trends in hospital capital budgets and procedure volumes, competitive dynamics in orthopedics and robotics, and any further analyst estimate revisions. Macroeconomic conditions and healthcare funding pressures in Europe also remain relevant to the company's international performance. I'm watching this closely as the earnings update could clarify the path forward.

Using AI Tools in My Analysis Workflow

In my day-to-day research, I often rely on Tickeron’s AI Trading Bots to monitor technical signals and trend patterns across holdings like SYK. These bots scan thousands of tickers and highlight strategies that have shown strength in recent conditions, helping me cross-check my own views without replacing fundamental analysis. The platform offers a range of approaches suited to different timeframes and risk levels, which I find useful when evaluating names facing execution challenges.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SYK

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for SYK turns negative, indicating new downward trend

SYK saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 52 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 58%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 20 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.

The Moving Average Convergence Divergence Histogram (MACD) for SYK turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 22 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Following a +2.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 178 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

The Aroon Indicator entered an Uptrend today. In 133 of 256 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1941 Stryker Way
Phone
+1 269 385-2600
Employees
56000
Web
https://www.stryker.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.